Novartis

Novartis delivered solid sales growth and core margin expansion in Q3, as priority brands and launches more than offset generic erosion.

We have raised our full-year 2026 guidance* for core operating income.

Link to press release: novartis.social/6018aLrvy

#NVSQ326

#NVSQ326 Novartis social media posts on Q3 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information.

#NVSQ326 Novartis social media posts on Q3 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis.

$NVS $NOVN

On Tuesday, October 27, Novartis will announce its Q3 2026 results.

Register to listen here: novartis.social/6019aIWpv

#NovartisNews $NVS $NOVN #NVSQ326

#Investors:

Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum from priority brands.

We remain on track to deliver our full-year guidance and mid-term outlook.*

Press release: novartis.social/6013v4CD7
Webcast: novartis.social/6014v4CDC

#NVSQ226
$NVS
$NOVN

#NVSQ226 Novartis social media posts on Q2 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information.

#NVSQ226 Novartis social media posts on Q2 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis.

$NVS $NOVN